Outlook Therapeutics (OTLK) revenue and earnings history
Outlook Therapeutics reported revenue of $1.41M for fiscal 2025 (year ended Sep 30, 2025), and net income of −$62.4M.
Over 10 years, from fiscal 2015 to fiscal 2025, revenue grew at a compound rate of −12.2% a year.
Revenue and net income, 11 fiscal years
Annual figures, newest first
| Fiscal year | Revenue | Operating income | Net income | Operating cash flow | Capital expenditure | Free cash flow | Stock-based pay | Share buybacks | Dividends paid | Cash at year end | Total debt at year end | Report |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025ended Sep 30, 2025 | $1.41M | −$67.1M | −$62.4M | −$51.8M | — | — | $8.9M | — | — | $8.08M | — | 10-K |
| 2024ended Sep 30, 2024 | — |
The latest quarter, insider trades and fund moves: Outlook Therapeutics (OTLK) on OQRO.
Common questions
What was Outlook Therapeutics's revenue in fiscal 2025?
$1.41M for the year ended Sep 30, 2025, as reported in its 10-K filed Dec 19, 2025.
How fast has Outlook Therapeutics's revenue grown?
From $5.22M in fiscal 2015 to $1.41M in fiscal 2025: a compound annual growth rate of −12.2% over 10 years. This is arithmetic on the filed figures and says nothing about the years ahead.
Has Outlook Therapeutics been profitable?
It reported a net loss in 11 of the years shown (2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025). The highest net income was −$30.1M in fiscal 2018.
Where these figures come from
The SEC’s companyfacts data: every figure Outlook Therapeutics tagged in XBRL in its annual and quarterly reports since 2009 (some reports carry a few earlier years as comparatives). For each fiscal year OQRO keeps the twelve-month totals from the annual report and the cash and debt at year end, and when a later report restates a year, the later figure. Read again whenever the company files.
Figures are as reported, in US dollars, with no adjustment for acquisitions, disposals or one-off items. Earnings per share are left out because a stock split changes them between reports. This page describes the past and is not investment advice. No language model wrote it.
